Lung Adenocarcinoma Expressing an EML4-ALK Fusion Transcript With Premature Stop Codons and Response to Alectinib: A...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Anaplastic Lymphoma Kinase (ALK) fusions are key drivers in lung adenocarcinoma.
• Conventional PCR assays may miss certain ALK rearrangements.
• Alternative mechanisms of ALK activation exist beyond standard fusion events.

Observation:

• An 80-year-old male patient with metastatic lung adenocarcinoma initially tested negative for ALK rearrangement by PCR.
• RNA-based hybrid capture sequencing identified an EML4-ALK fusion transcript.
• The identified fusion contained a premature stop codon, seemingly preventing protein expression.

Findings:

• Immunohistochemistry revealed significant ALK protein overexpression.
• This suggests alternative translation initiation sites were utilized.
• The patient demonstrated a substantial clinical response to alectinib treatment.

Implications:

• This case emphasizes the critical need for utilizing multiple molecular diagnostic techniques to identify actionable gene fusions.
• Comprehensive testing ensures accurate patient stratification for targeted therapies.
• Understanding alternative ALK activation mechanisms can improve treatment strategies in lung cancer.